FindTrial
Sign In

Exploratory Study to Investigate the Reparative and Regenerative Potential of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Participating in the CARE MS I and MS II Studies

An Exploratory Study to Investigate the Reparative and Regenerative Potential of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis: A Multi-Parametric Non-Conventional MRI Sub-Study in Patient Participating in the CARE MS I and CARE MS II Studies

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01020370
Enrollment
Unknown
Registered
2009-11-25
Start date
Unknown
Completion date
Unknown
Last updated
2009-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Keywords

Patients with RRMS who are participating in the CARE MS I and CARE MS II

Brief summary

The primary goal of this study will be to explore the reparative and regenerative potential of alemtuzumab in RRMS patients who are participating in the CARE MS I and CARE MS II studies using conventional and non-conventional MRI sequences.

Interventions

None listed

Sponsors

Wayne State University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Participating in either the CARE MS I or CARE MS II studies

Exclusion criteria

* Not a participant in the CARE MS I or CARE MS II studies

Design outcomes

Primary

MeasureTime frame
Explore the reparative and regenerative potential of alemtuzumab in RRMS patients who are participating in the CARE MS I and CARE MS II studies—

Secondary

MeasureTime frame
Compare the effect of alemtuzumab to interferon beta-1a SC on non-conventional MRI outcomes—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026